TrialDiabetes care2014

Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.

Peter E Linz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.